Opaleye Management as of June 30, 2019
Portfolio Holdings for Opaleye Management
Opaleye Management holds 43 positions in its portfolio as reported in the June 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Codexis (CDXS) | 7.6 | $25M | 1.4M | 18.43 | |
| Imprimis Pharmaceuticals | 5.9 | $19M | 2.2M | 8.70 | |
| Axogen (AXGN) | 5.4 | $18M | 900k | 19.80 | |
| Epizyme | 5.2 | $17M | 1.4M | 12.55 | |
| Uniqure Nv (QURE) | 4.9 | $16M | 205k | 78.15 | |
| Odonate Therapeutics Ord | 4.8 | $16M | 425k | 36.69 | |
| Ocular Therapeutix (OCUL) | 4.0 | $13M | 3.0M | 4.40 | |
| Amarin Corporation (AMRN) | 3.8 | $13M | 645k | 19.39 | |
| Blueprint Medicines (BPMC) | 3.6 | $12M | 125k | 94.33 | |
| Cerecor | 3.4 | $11M | 2.2M | 5.11 | |
| Audentes Therapeutics | 3.2 | $11M | 280k | 37.86 | |
| Ptc Therapeutics I (PTCT) | 3.1 | $10M | 226k | 45.00 | |
| Cytokinetics | 3.1 | $10M | 900k | 11.25 | |
| Tg Therapeutics (TGTX) | 3.0 | $9.9M | 1.2M | 8.65 | |
| Eidos Therapeutics | 2.9 | $9.5M | 306k | 31.08 | |
| Lexicon Pharmaceuticals (LXRX) | 2.8 | $9.3M | 1.5M | 6.29 | |
| Eton Pharmaceuticals (ETON) | 2.6 | $8.5M | 1.1M | 7.90 | |
| Magenta Therapeutics | 2.4 | $7.9M | 535k | 14.75 | |
| Tricida | 2.4 | $7.7M | 195k | 39.46 | |
| Deciphera Pharmaceuticals (DCPH) | 2.1 | $7.0M | 310k | 22.55 | |
| Fibrogen (FGEN) | 2.1 | $6.8M | 150k | 45.18 | |
| Biohaven Pharmaceutical Holding | 2.0 | $6.6M | 150k | 43.79 | |
| Chimerix (CMRX) | 1.9 | $6.4M | 1.5M | 4.32 | |
| Xoma Corp Del (XOMA) | 1.8 | $5.9M | 400k | 14.86 | |
| Avenue Therapeutics | 1.8 | $5.9M | 930k | 6.30 | |
| Ironwood Pharmaceuticals (IRWD) | 1.8 | $5.7M | 525k | 10.94 | |
| ACADIA Pharmaceuticals (ACAD) | 1.6 | $5.3M | 200k | 26.73 | |
| Arvinas Ord (ARVN) | 1.5 | $4.8M | 220k | 21.99 | |
| Vermillion | 1.1 | $3.8M | 4.3M | 0.89 | |
| Zymeworks | 1.1 | $3.7M | 170k | 22.02 | |
| Strongbridge Bioph shs usd | 1.1 | $3.6M | 1.1M | 3.13 | |
| Fortress Biotech | 1.1 | $3.5M | 2.4M | 1.50 | |
| Viking Therapeutics (VKTX) | 1.0 | $3.3M | 400k | 8.30 | |
| Aimmune Therapeutics | 0.8 | $2.7M | 130k | 20.83 | |
| Aquestive Therapeutics (AQST) | 0.8 | $2.5M | 590k | 4.20 | |
| Synthorx | 0.7 | $2.1M | 158k | 13.51 | |
| Ra Pharmaceuticals | 0.5 | $1.5M | 51k | 30.08 | |
| Fennec Pharmaceuticals (FENC) | 0.4 | $1.2M | 295k | 4.00 | |
| ArQule | 0.3 | $1.1M | 100k | 11.01 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.3 | $900k | 36k | 25.00 | |
| Protalix BioTherapeutics | 0.1 | $470k | 1.0M | 0.47 | |
| Azurrx Biopharma | 0.1 | $247k | 145k | 1.70 | |
| Biolinerx Ltd-spons | 0.0 | $90k | 250k | 0.36 |
